GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® ...
Repatha is now available for a monthly cash price of $239, through AmgenNow and GoodRx. Repatha (evolucumab) is now avaliable ...
Amgen has joined the wave of major drugmakers setting up direct-to-consumer programs amid President Donald Trump’s call for more DTC options to lower U.S. drug prices. The "AmgenNow" program, launched ...
Amgen makes Repatha available through AmgenNow, a direct-to-patient programme in the US: Thousand Oaks, California Wednesday, October 8, 2025, 17:00 Hrs [IST] Amgen announced the ...
Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash ...
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Amgen's late-stage study of human monoclonal antibody Repatha hit its dual primary targets, demonstrating it significantly reduced the risk of major adverse cardiovascular events in individuals ...
Cardiologists often struggle to assess heart attack risk. New startups using AI could help.
Clinical Trials Arena on MSN
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
The VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary endpoints, proving that Repatha can significantly reduce the risk of MACE in ...
Amgen said yesterday that its cholesterol-lowering injection Repatha cut the risk of a composite of heart disease death, ...
Amgen’s phase 3 VESALIUS-CV trial meets primary endpoints in a cardiovascular primary prevention study of 12,000 patients: Thousand Oaks, California Saturday, October 4, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback